The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis

The Effect of Iron Supplementation on FGF23 in Chronic Kidney Disease Patients: a Systematic Review and Time-Response Meta-Analysis

Fibroblast growth factor 23 (FGF23) gene is found to be responsible for autosomal dominant hypophosphatemic rickets, and is highly expressed in chronic kidney disease (CKD) and end-stage renal disease patients with iron deficiency anemia (IDA). We evaluated the efficacy of different iron treatments...

Full description

Saved in:
Bibliographic Details
Published in:Biological trace element research Vol. 199; no. 12; pp. 4516 - 4524
Main Authors: Abu-Zaid, Ahmed, Magzoub, Duha, Aldehami, Mohammad Abdulrahman, Behiry, Abdulrahman Adel, Bhagavathula, Akshaya Srikanth, Hajji, Raouf
Format: Journal Article
Language:English
Published: New York Springer US 01-12-2021
Springer Nature B.V
Subjects:
Anaemia
Analysis
Anemia
Biochemistry
Biomedical and Life Sciences
Biotechnology
Clinical trials
Confidence intervals
Control
Dialysis
End-stage renal disease
Fibroblast growth factor 23
Growth factors
Hypophosphatemia
Intravenous administration
Iron
Iron deficiency
Kidney diseases
Kidneys
Life Sciences
Meta-analysis
Nutrient deficiency
Nutrition
Oncology
Patients
Placebos
Reduction
Rickets
Subgroups
Systematic review
Therapy
Renal dialysis
Iron
Chronic kidney disease
Ferric citrate
Anemia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fibroblast growth factor 23 (FGF23) gene is found to be responsible for autosomal dominant hypophosphatemic rickets, and is highly expressed in chronic kidney disease (CKD) and end-stage renal disease patients with iron deficiency anemia (IDA). We evaluated the efficacy of different iron treatments on FGF23 levels in dialysis-dependent and non-dialysis-dependent CKD patients with IDA. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing different types of iron treatment versus placebo in CKD patients up to May 2020. We investigated the efficacy of iron treatment on the levels of FGF23 and C-terminal FGF23 (cFGF23) in CKD patients. We estimated weighted mean differences (WMDs) and 95% confidence intervals (CIs) using the random-effects model. Nine studies with 11 arms were included in the meta-analysis. Overall, iron treatment showed a significant reduction in FGF23 levels compared to control group (WMD: − 60.56 pg/ml, 95% CI: − 92.17, − 28.95). Compared to placebo, subgroup analysis showed that oral iron therapy (WMD: − 6.98 pg/ml, 95% CI: − 10.66, − 3.31) was more effective than intravenous (IV) iron therapy (WMD: 4.90 pg/ml, 95% CI: − 12.03, 21.83) on FGF23 levels. There was no significant change in cFGF23 levels between iron treatment and control group (WMD: − 64.72 Ru/ml, 95% CI: − 147.69, 18.25). Subgroup analysis showed that oral iron therapy resulted in a significant reduction in cFGF23 levels compared to control group (WMD: − 150.48 RU/ml, 95% CI: − 151.31, − 149.65). In conclusion, iron treatment was associated with a significant decrease in FGF23 levels in CKD patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-4
content type line 23
ObjectType-Undefined-3
ISSN:0163-4984
1559-0720
DOI:10.1007/s12011-021-02598-1